At the European Society of Cardiology Congress 2024, Edwards Lifesciences (EW) announced the results from the RHEIA Trial — the first-ever study focused exclusively on women receiving transcatheter aortic valve implantation (TAVI). The outcome revealed that Edwards SAPIEN 3 or SAPIEN 3 Ultra valves have led to superior outcomes for women compared with those receiving surgical aortic valve replacement (SAVR). The latest development will strongly boost the company's Transcatheter Aortic Valve Replacement (TAV ...